In this article
Study on Adjuvant Therapy for Rare Gastrointestinal Tumors
A study from the University of Cincinnati School of Medicine at the Annual Cancer Symposium on Surgical Oncology in Chicago on March 24, 2018 showed that adjuvant or additional treatment after surgical resection of rare types of gastrointestinal tumors does not improve patients ’ Survival rate. These findings provide in-depth insights into the treatment options for these types of cancer patients, and may no longer require prescribed adjuvant therapy, maintain quality of life, and save money.
In this study, the researchers used the tumor data of stage I to III patients with surgically removed ampulla from 1998 to 2006 (5,298 patients) in the National Cancer Database of the American College of Surgeons to compare only surgery (3,785), surgery plus Patients with additional chemotherapy (316) and those undergoing surgery plus additional chemotherapy and radiotherapy (1,197) were analyzed for overall survival.
Survival Outcomes for Surgically Resected Ampullary Tumors
29% (1,513) of patients who underwent surgical resection of ampullary tumors received adjuvant therapy. Adjuvant therapy is more commonly used in patients with stage III, lymph node tumors, and positive surgical margins. However, there was no significant difference in stage-specific survival rates among patients with stage I, II, or III receiving any treatment. Similarly, patients with lymph node tumors and positive surgical margins received no adjuvant survival benefit. This national analysis showed that even for patients with aggressive disease, the adjuvant treatment of surgically removed ampullary tumors did not show any survival benefit.
Role of Genetic Testing and Multi-Platform Analysis
Therefore, no matter what kind of , any cancer that has progressed, it is necessary to evaluate the subtypes of cancer and their differences at the cellular level. Only through genetic testing can we determine the molecular level changes of patients and guide more precise treatment. The multi-platform atlas analysis of the United States (the authoritative cancer guidance drug company in the United States) can not only analyze cancer driver genes at the genetic level, but also combine RNA and protein detection to analyze multi-level molecular mechanisms, comprehensively evaluate tumor characteristics, and comprehensively guide symptomatic medication. More detailed information can be consulted on the Global Oncologist Network.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Alysha Mendossa
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.